That is, any factor that affects diagnostic intensity and particularly PSA testing will inevitably affect observed prostate cancer incidence, making it difficult to distinguish between factors that influence disease development and those that influence disease detection. This evidence concerns the gene KLK3 and prostate carcinoma.